Safety and Antiviral Study of ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-resistant Chronic Hepatitis B

Study Identifier:
ACH443-005
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Other

Study Details

Medical Condition
  • Hepatitis
Study Drug
  • Drug: ACH126, 433
Date
Jul 2002 - N/A
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years
Requirements Information
Sex
Female & Male
Age
18+ years

Study Details

Medical Condition
  • Hepatitis
Study Drug
  • Drug: ACH126, 433
Date
Jul 2002 - N/A
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years years
Requirements Information

Protocol Summary

The purpose of this study was to determine the safety and antiviral hepatitis B virus (HBV) activity of ACH126, 433 in the treatment of adults with lamivudine-resistant chronic hepatitis B.

Trial Locations

Location
Status
Location
Clinical Trial Site
Los Angeles, California, United States, 90048
Status
N/A
Location
Clinical Trial Site
Orange, California, United States, 92868
Status
N/A
Location
Clinical Trial Site
Pasadena, California, United States, 91105
Status
N/A
Location
Clinical Trial Site
San Francisco, California, United States, 94143
Status
N/A
Location
Clinical Trial Site
Miami, Florida, United States, 33136
Status
N/A
Location
Clinical Trial Site
Chicago, Illinois, United States, 60612
Status
N/A